Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernhard Ludvik

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
Obesity Surgery|June 27, 2019
Albuminuria in Patients with Morbid Obesity and the Effect of Weight Loss Following Bariatric SurgeryJohanna Maria Brix, Carsten Thilo Herz, Hans Peter Kopp, et al.
Lancet (London, England)|April 1, 2025
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trialMarc P Bonaca, Andrei-Mircea Catarig, Kim Houlind, et al.
Journal of the American College of Cardiology|January 14, 2026
Improvement in Walking Distance With Semaglutide in Smokers With Peripheral Artery Disease: STRIDE Trial Subgroup AnalysisHarald Sourij, Ecenur Guder Arslan, Andrei-Mircea Catarig, et al.
Diabetes, Obesity & Metabolism|February 11, 2025
Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomesThomas Forst, Christophe De Block, Stefano Del Prato, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 18, 2024
Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetesMarc P Bonaca, Andrei-Mircea Catarig, Yasemin Hansen, et al.
Obesity Surgery|March 19, 2016
Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D DeficiencyMaria Luger, Renate Kruschitz, Christian Kienbacher, et al.
Journal of the American College of Cardiology|September 2, 2025
Sex Differences in Effectiveness of Semaglutide in Patients with Peripheral Artery Disease: The STRIDE TrialSubodh Verma, Andrei-Mircea Catarig, Kim Houlind, et al.
European Heart Journal|March 4, 2026
Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trialJoakim Nordanstig, Ecenur Guder Arslan, Andrei-Mircea Catarig, et al.
Diabetes Care|June 21, 2025
Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind TrialNeda Rasouli, Ecenur Guder Arslan, Andrei-Mircea Catarig, et al.
Obesity Surgery|July 4, 2018
Changes in Bone Mineral Density Following Weight Loss Induced by One-Anastomosis Gastric Bypass in Patients with Vitamin D SupplementationMaria Luger, Renate Kruschitz, Eva Winzer, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
Obesity Surgery|June 27, 2019
Albuminuria in Patients with Morbid Obesity and the Effect of Weight Loss Following Bariatric SurgeryJohanna Maria Brix, Carsten Thilo Herz, Hans Peter Kopp, et al.
Lancet (London, England)|April 1, 2025
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trialMarc P Bonaca, Andrei-Mircea Catarig, Kim Houlind, et al.
Journal of the American College of Cardiology|January 14, 2026
Improvement in Walking Distance With Semaglutide in Smokers With Peripheral Artery Disease: STRIDE Trial Subgroup AnalysisHarald Sourij, Ecenur Guder Arslan, Andrei-Mircea Catarig, et al.
Diabetes, Obesity & Metabolism|February 11, 2025
Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomesThomas Forst, Christophe De Block, Stefano Del Prato, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 18, 2024
Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetesMarc P Bonaca, Andrei-Mircea Catarig, Yasemin Hansen, et al.
Obesity Surgery|March 19, 2016
Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D DeficiencyMaria Luger, Renate Kruschitz, Christian Kienbacher, et al.
Journal of the American College of Cardiology|September 2, 2025
Sex Differences in Effectiveness of Semaglutide in Patients with Peripheral Artery Disease: The STRIDE TrialSubodh Verma, Andrei-Mircea Catarig, Kim Houlind, et al.
European Heart Journal|March 4, 2026
Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trialJoakim Nordanstig, Ecenur Guder Arslan, Andrei-Mircea Catarig, et al.
Diabetes Care|June 21, 2025
Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind TrialNeda Rasouli, Ecenur Guder Arslan, Andrei-Mircea Catarig, et al.
Obesity Surgery|July 4, 2018
Changes in Bone Mineral Density Following Weight Loss Induced by One-Anastomosis Gastric Bypass in Patients with Vitamin D SupplementationMaria Luger, Renate Kruschitz, Eva Winzer, et al.
Pageof 13